Table 3

Effect of following a sustained treat-to-target strategy on remission outcomes 3 months later*

DAS44 sustained remission
(OR (95% CI))
DAS28-ESR sustained remission
(OR (95% CI))
ACR/EULAR Boolean sustained remission
(OR (95% CI))
CDAI sustained remission
(OR (95% CI))
SDAI sustained remission
(OR (95% CI))
Sustained T2T 1.19 (1.03 to 1.39) 1.23 (1.06 to 1.44) 1.49 (1.24 to 1.81) 1.45 (1.19 to 1.77) 1.52 (1.27 to 1.82)
  • *All models adjusted for age, gender, disease duration and country. Sustained treat-to-target was considered followed if T2T was followed in ≥2 subsequent visits. T2T was considered being followed: (i) if a patient had already a disease activity score below the target (DAS <1.6; DAS <2.4 for LDA definition) and treatment was correctly not intensified; or (ii) if treatment was intensified on a DAS ≥1.6 (or DAS ≥2.4 for LDA definition).

  • ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; DAS44, 44-joint disease activity score; DAS28-ESR, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; LDA, low disease activity; SDAI, Simple Disease Activity Index; T2T, treat-to-target.